Showing results (121-130 of 222) with videos related to

Sort By:
Pageof 23
Cancer Medicine|April 1, 2024
Characterization and impact of non-canonical WNT signaling on outcomes of urothelial carcinomaMargaret Meagher, Harris Krause, Andrew Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2022
Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate CancerUlka N Vaishampayan, Archana Thakur, Wei Chen, et al.
JCO Oncology Practice|December 3, 2019
Unpacking Trial Offers and Low Accrual Rates: A Qualitative Analysis of Clinic Visits With Physicians and Patients Potentially Eligible for a Prostate Cancer Clinical TrialLauren M Hamel, David W Dougherty, Terrance L Albrecht, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2013
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumorsElisabeth I Heath, Jeffrey Infante, Lionel D Lewis, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2001
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumorsE I Heath, S O'Reilly, R Humphrey, et al.
Cancer Medicine|December 21, 2022
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT studySusan Eggly, Nicole Senft, Seongho Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerElisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Croatian Medical Journal|May 16, 2000
Joining together to combat povertyI Heath, A Haines, Z Malenica, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2024
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancerUlka N Vaishampayan, Marianne Keessen, Robert Dreicer, et al.
Kidney Cancer (Clifton, Va.)|November 26, 2019
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)Timothy W Synold, Melissa Plets, Catherine M Tangen, et al.
Pageof 23